Cyclohexylformamide

Cyclohexylformamide

SCHEMBL817895

O=CNC1CCCCC1.[MgH2]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 5/20 0.94
ADH1A P07327 5/20 0.94
ADH1C P00326 4/20 0.94
ADH4 P08319 2/20 0.94
ADH7 P40394 3/20 0.89
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 1/20 0.50
LMNA P02545 1/20 0.42
EPHX1 P07099 6/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CA1 P00915 2/20 0.40
CA12 O43570 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
MAPT P10636 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP3A4 P08684 1/20 0.40
EPHX2 P34913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2109469 0.97 ADH1B (1.00) ADH1BADH1AADH1CADH4ADH7
SCHEMBL645299 0.97 ADH1B (1.00) ADH1BADH1AADH1CADH4ADH7
SCHEMBL9206597 0.97 ADH1B (1.00) ADH1BADH1AADH1CADH4ADH7
SCHEMBL245391 0.97 ADH1B (1.00) ADH1BADH1AADH1CADH4ADH7
SCHEMBL2112448 0.97 ADH1B (1.00) ADH1BADH1AADH1CADH4ADH7
SCHEMBL22988657 0.97 ADH1B (1.00) ADH1BADH1AADH1CADH4ADH7
Cyclohexylformamide SCHEMBL26146 0.97
Cyclohexylformamide SCHEMBL28496813 0.97 ADH1B (1.00) ADH1BADH1AADH1CADH4ADH7
Cyclohexylformamide SCHEMBL815680 0.94 ADH1B (0.94) ADH1BADH1AADH1CADH4ADH7
Cyclohexylformamide SCHEMBL816897 0.94 ADH1B (0.94) ADH1BADH1AADH1CADH4ADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153545-B2 Process for homo—or copolymerization of conjugated olefins STYRON EUROPE GMBH (CH) 2012-04-10 US disclosed
US-20110160041-A1 PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS STYRON EUROPE GMBH 2011-06-30 US disclosed
US-7915194-B2 Process for homo- or copolymerization of conjugated olefins STYRON EUROPE GMBH (CH) 2011-03-29 US disclosed
US-20100248947-A1 PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS DOW GLOBAL TECHNOLOGIES INC. (US) 2010-09-30 US disclosed
US-7612009-B2 Process for homo-or copolymerization of conjugated olefines DOW GLOBAL TECHNOLOGIES, INC. (US) 2009-11-03 US disclosed
US-20060142145-A1 Process for homo-or copolymerization of conjugated olefines TRINSEO EUROPE GMBH (CH) 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160041-A1 PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS F12, ETFB, F2 ADH1B 1366/4885ADH1A 959/4885ADH1C 687/4885
US-20060142145-A1 Process for homo-or copolymerization of conjugated olefines ETFB, F12, F2 ADH1B 970/4885ADH1A 930/4885ADH1C 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.